This review considers the potential therapeutic role of inhibiting the cytokine tumour necrosis factor alpha in the treatment of patients with heart failure.
Does inhibition of tumour necrosis factor alpha improve outcomes in patients with heart failure?
This review discusses the potential therapeutic role of inhibiting tumour necrosis factor alpha to address the inflammatory state in heart failure.
Heart failure is a systemic disorder characterised by tissue hypoxia and secondary organ dysfunction which occurs in response to various myocardial insults that include ischaemia, viral infections, and toxins. In addition to maladaptive neurohumoral activation, heart failure is associated with an inflammatory state that appears to have a detrimental effect on cardiac function and prognosis. This has led to the suggestion that anti-inflammatory interventions may have therapeutic potential in the symptomatic and prognostic treatment of patients with heart failure. This review considers the role of inhibition of the cytokine tumour necrosis factor alpha in the treatment of heart failure.
Henriksen et al. (2002) conducted a review in Heart failure. Inhibition of tumour necrosis factor alpha was evaluated. This review considers the potential therapeutic role of inhibiting the cytokine tumour necrosis factor alpha in the treatment of patients with heart failure.